Rethinking ustekinumab: An essential reconsideration for moderate-to-severe Crohn's disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Rethinking ustekinumab: An essential reconsideration for moderate-to-severe Crohn's disease

Published:2024-08 Issue: Volume: Page:
ISSN:1590-8658
Container-title:Digestive and Liver Disease
language:en
Short-container-title:Digestive and Liver Disease

Author:

Farid Isma^ORCID,Shahid Maryam^ORCID,Shahzad Maryum^ORCID

Publisher

Elsevier BV

Reference8 articles.

1. Real-world effectiveness and safety of ustekinumab in bio-naive patients with moderate-to-severe Crohn's disease: a Canadian multi-center study;Bessissow;Dig Liver Dis,2024

2. Improving IBD outcomes in the era of many treatment options;Kobayashi;Nat Rev Gastroenterol Hepatol,2023

3. Long-term real-world effectiveness and safety of ustekinumab in Crohn's disease patients: the SUSTAIN study;Chaparro;Inflamm Bowel Dis,2022

4. Genetics and epigenetics of IBD;Annese;Pharmacol Res,2020

5. Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab- and ustekinumab-treated patients with inflammatory bowel disease—a prospective multicentre cohort study;Asscher;Aliment Pharmacol Ther,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3